BCG Vaccine Linked to Lower Dementia Risk

Johns Hopkins researchers report evidence that the tuberculosis vaccine may slow dementia onset through trained immunity in cells.

Updated on Nov. 21, 2026 in Alzheimer’s

Clear unlabeled glass vials and a plain syringe on a pale laboratory bench under soft daylight.
Johns Hopkins researchers report evidence that the tuberculosis vaccine BCG may slow dementia onset through trained immunity in cells. AI Illustration. Upload story photo >

Live Poll

Would you get a BCG vaccine if doctors said it might lower dementia risk?

Johns Hopkins University researchers found evidence that the BCG tuberculosis vaccine reduces dementia risk. Their paper, published in Science Advances, reports that mice given BCG showed fewer hallmark dementia signs, such as memory loss, than unvaccinated mice.

Why it matters

The findings suggest a possible link between trained immunity and the stalling of dementia onset, a question with major implications for an aging population. Earlier 2026 work from Massachusetts General Hospital and Harvard University also reported a potential biological explanation for the BCG-dementia connection.

The evidence comes from mouse experiments comparing BCG-administered and unvaccinated animals, which showed fewer memory-loss and other dementia markers in the vaccinated group. The detailed biological mechanism remains under study, and human effects have not been established.

The players

Johns Hopkins University

A private research university in Baltimore, Maryland, known for its medical and public health research programs.

Dr William Bishai

Study corresponding author and co-director of the Johns Hopkins Center for Tuberculosis Research, a leading TB researcher.

The details

The BCG injection partly prompted trained immunity, in which first responder immune system cells take on an expanded role after stimulation. The vaccine also reduced hyperinflammation in the brain and altered markers linked to Alzheimer's disease, including in fluid surrounding the brain and spinal cord.

Timeline

  1. Earlier in 2026: Massachusetts General Hospital and Harvard researchers reported a potential biological explanation for the BCG-dementia link.

  2. November 21, 2026: The Johns Hopkins study was published in Science Advances and reported.

Research Context

The study extends the Johns Hopkins Center for Tuberculosis Research's work on BCG into neurodegeneration, a line of inquiry that parallels the earlier 2026 Massachusetts General Hospital and Harvard findings on the same vaccine. Together, these reports point toward trained immunity as a possible shared pathway for the BCG-dementia association.

Because the evidence so far comes from mice, the BCG vaccine should not be seen as a dementia treatment for people today. Readers interested in its potential should watch for human trials before drawing any personal health conclusions.

The takeaway

Early animal research points to trained immunity as a possible route to slowing dementia, but human evidence is still needed. Readers should treat the BCG finding as a promising lead rather than established medical advice.

Further reading

Explore more on Alzheimer’s research and risk factors.

Source note: This article includes information reported by The Star.

Live Poll

Would you get a BCG vaccine if doctors said it might lower dementia risk?